Partnering
We partner to deliver best-in-class treatment options to patients
We engage with partners so we can focus on our core competencies. Zealand’s strength lies in therapeutic peptide discovery, design and development, which has led to our R&D pipeline of differentiated candidates targeting obesity, rare diseases, and chronic inflammation.
Our strategy is to pursue global co-development and commercialization partnerships that complement and extend our capabilities to deliver new therapies to patients with unmet medical needs.
We engage with partners across the value chain. We also have partnerships with leading academic and scientific institutions, contract research organizations (CROs), contract manufacturing and development organizations (CDMOs), and distribution partners.
Our partners
Roche
In March 2025, Zealand Pharma and Roche entered a global collaboration and license agreement to develop petrelintide, our long-acting amylin analog with best-in-class potential. The two companies will co-develop and co-commercialize petrelintide and combination products with petrelintide, including a fixed-dose combination product of petrelintide and CT-388, Roche’s lead incretin asset and potential best-in-class GLP-1/GIP receptor dual agonist. This collaboration reflects our shared vision to develop petrelintide as a future foundational therapy for weight management and related comorbidities and aims to unlock its full value, redefining the standard of care for people with overweight and obesity by establishing the leading amylin-based franchise.
Read the press release for more information and terms of the agreement:
Visit website
Boehringer Ingelheim
In 2011, Zealand Pharma and Boehringer Ingelheim partnered to develop drug candidates for type 2 diabetes and obesity. As part of the agreement, survodutide, a long-acting glucagon/GLP-1 receptor dual agonist, is licensed to Boehringer Ingelheim.
Survodutide is being developed for the treatment of obesity and MASH, with Boehringer Ingelheim solely responsible for development and commercialization globally. Zealand Pharma is eligible to receive up to EUR 315 million in outstanding milestone payments, plus tiered royalties ranging from high single-digit to low double-digit percentages on potential global sales by Boehringer Ingelheim.
Visit website
DEKA Research & Development Corp
In 2021, Zealand partnered with DEKA Research & Development Corp. and affiliates to develop a continuous infusion pump to be used in combination with dasiglucagon, an investigational agent designed for patients living with congenital hyperinsulinism. The agreement covers the technical development of the pump system as well as associated manufacturing and commercialization activities.
Visit website
OTR Therapeutics
On December 11, 2025, Zealand Pharma announced a multi-program strategic collaboration and license agreement, with OTR Therapeutics, a biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies for unmet medical needs, to discover and develop novel therapeutics for metabolic diseases.
The collaboration brings together Zealand Pharma’s deep expertise in obesity and metabolic health with OTR Therapeutics’ proprietary R&D platform, scientific rigor, and unique strengths in speed, efficiency, and quality - supported by strong ties to regional R&D networks - to develop transformative treatment options for millions of people living with metabolic diseases. By pursuing next-generation therapeutics, we will meaningfully expand treatment options.
Read the press release for more information about the partnership.
Visit websiteAccessing cutting-edge technology through research collaborations
We also have an interest in novel ideas for biological targets which could be addressed with peptide therapeutics as well as novel peptide chemistry.
In addition, we are focused on identifying novel technologies that allow alternative routes of administration, improve drug-like properties, and facilitate conjugation of additional moieties to peptides.
